Risk factors associated with hyporesponse to erythropoietin in chronic kidney disease patients on hemodialysis who present anemia.
A multicenter observational study.
DOI:
https://doi.org/10.56867/68Keywords:
Renal replacement therapy, hemodialy4sis, erythropoietin hyporesponsiveness, resistance, erythropoiesis, AnemiaAbstract
Introduction: Anemia is common in patients with chronic kidney disease (CKD) and is associated with higher mortality and lower quality of life. The introduction of recombinant erythropoietin represented an advance in the management of anemia; however, an increase in the rate of cardiovascular disease and stroke was observed. Usually, anemia is partially corrected, with cases of hyporesponsiveness to treatment being found.
Methods: Observational, analytical, multicenter case-control study.
Results: Of 784 patients, 123 presented hyporesponsiveness (15.69%). The risk factors identified were: female sex (OR=2.188), age less than 50 years (OR=3.846), body mass index less than 23 kg/m² (OR=1.598), use of renin-angiotensin system blockers (OR=1. 915), albumin less than 4.0 (OR=5.286), ferritin greater than or equal to 800 ng/ml (OR=4.775), transferrin saturation index (TSI) less than 20% (OR=5.803) and parathormone greater than or equal to 500 μg/ml (OR=2.183). In the multivariate model, these variables were significant (P <0.05, R2: 0.56) except for Diabetes and BMI (P >0.05).
Conclusion: Female sex, age less than 50 years, BMI less than 23 kg/m², ARB use, low albumin, elevated ferritin, low TSI, and elevated parathormone are risk factors associated with erythropoietin hyporesponsiveness

Downloads
Published
Issue
Section
License
Copyright (c) 2024 Carlos Eduardo Pérez Tulcanaza , Jorge Fabián Chonata Quinteros , Jorge Washington Vélez (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.